Zai Lab Limited

Equities

ZLAB

US98887Q1040

Pharmaceuticals

Real-time Estimate Cboe BZX 03:53:28 2024-02-21 pm EST 5-day change 1st Jan Change
19.84 USD +3.09% Intraday chart for Zai Lab Limited +2.06% -27.59%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Asian Equities Traded in the US as American Depositary Receipts Open Week Higher in Monday Trading MT
Zai Lab Enters Into Loan Facility Deals MT
Asian Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Trading MT
Asian Equities Traded in the US as American Depositary Receipts Open Week Lower in Monday Trading MT
Zai Lab Announces the New England Journal of Medicine Publication Demonstrating Durable Clinical Activity of Repotrectinib in Patients with Advanced ROS1 Fusion-Positive NSCLC CI
Transcript : Zai Lab Limited Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-08-2024 03:45 PM
Asian Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading MT
Zai Lab Reports Chief Operating Officer Joshua Smiley Purchased 4,000 ADSs Under Trading Plan; Shares Jump Premarket MT
Morgan Stanley Starts Coverage on Zai Lab with Overweight Rating, $47.50 Price Target MT
Zai Lab Shares Climb as Vyvgart, Nuzyra, Zejula Added to 2023 China Reimbursement Drug List MT
Tech, Telecoms Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Lower in Wednesday Trading MT
Sector Update: Health Care Stocks Stronger Late Afternoon MT
Zai Lab Says China Added Vyvgart, Nuzyra, Zejula to 2023 Reimbursement Drug List MT
Zai Lab's Vyvgart Injection Added to China's National Reimbursement Drug List MT
Zai Lab Limited Announces the First Listing of VYVGART(R) (efgartigimod alfa injection) and Other Updates in China's National Reimbursement Drug List CI
Tech Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Lower in Monday Trading MT
Asian Equities Traded in the US as American Depositary Receipts Edge Higher in Wednesday Trading MT
Financial Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Higher in Friday Trading MT
Zai Lab Insider Bought Shares Worth $134,650, According to a Recent SEC Filing MT
Tech Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Lower in Monday Trading MT
Tech Stocks Nudge Asian Equities Traded in the US as American Depositary Receipts Slightly Higher Thursday Morning MT
Telecoms Firms Lead Asian Equities Traded in the US as American Depositary Receipts Lower in Wednesday Trading MT
Transcript : Zai Lab Limited, Q3 2023 Earnings Call, Nov 08, 2023
Zai Lab's Q3 Loss Narrows, Revenue Increases MT
Zai Lab's Q3 Loss Narrows as Revenue Rises MT
Chart Zai Lab Limited
More charts
Zai Lab Ltd is a biopharmaceutical company. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including in the fields of oncology, autoimmune and infectious diseases. The Company has a broad pipeline of proprietary drug candidates that range from discovery stage to late-stage clinical programs. These include three drug candidates with greater China rights and three drug candidates with global rights. The greater China rights drug candidates include Niraparib (ZL-2306), Omadacycline (ZL-2401) and ZL-2301. The global rights drug candidates include Fugan (ZL-3101), ZL-2302 and ZL-1101.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
19.24 USD
Average target price
62.9 USD
Spread / Average Target
+226.90%
Consensus
  1. Stock
  2. Equities
  3. Stock Zai Lab Limited - Nasdaq
  4. News Zai Lab Limited
  5. Financial Firms Lead Asian Equities Traded in the US as American Depositary Receipts Lower in Monday Trading
+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019
Replicate our performance
fermer